Immuron Ltd

IMRN

Company Profile

  • Business description

    Immuron Ltd is a commercial- and clinical-stage biopharmaceutical company focused on the development and commercialization of specifically targeted polyclonal antibodies. Its oral polyclonal antibodies offer delivery within the GI tract and can target viruses or bacteria and neutralize toxins at mucosal surfaces. The Company markets Travelan in Australia, an over-the-counter orally administered passive immunotherapeutic product indicated to reduce the risk of traveler's diarrhea and minor gastrointestinal disorders. Its products include Travelan, ProIBS and Protectyn. Its segments are Research and Development and Hyper-immune products, with Hyper-immune products generating maximum revenue. Australia generates maximum revenue.

  • Contact

    25-37, Chapman Street
    Unit 10
    Blackburn
    MelbourneVIC3130
    AUS

    https://www.immuron.com.au

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    30 June 2027

    Employees

    8

Stocks News & Analysis

stocks

Overvalued ASX share has overly ambitious profit target

We think the new profit target is aggressive and unlikely to be met.
stocks

7 undervalued US stocks that crushed earnings

Arista and GE Vernova remain among the cheapest Morningstar-covered stocks after strong earnings beats.
stocks

Undervalued ASX share hitting on all cylinders

Strong performance across all segments in latest earnings release.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries9,165.4039.10-0.42%
CAC 408,352.0016.91-0.20%
DAX 4026,598.64151.31-0.57%
Dow JONES (US)51,608.17739.38-1.41%
FTSE 10010,881.5521.01-0.19%
HKSE23,753.84116.240.49%
NASDAQ24,509.76626.52-2.49%
Nikkei 22559,662.021,480.33-2.42%
NZX 50 Index14,260.8542.92-0.30%
S&P 5007,416.59145.08-1.92%
S&P/ASX 2009,044.7037.50-0.41%
SSE Composite Index3,602.5731.78-0.87%

Market Movers